The estrogen receptor: A model for molecular medicine

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 1980-1989

  Jensen, Elwood V ^a   Jordan, V Craig ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CLOMIFENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHAMOXYTRIPHETOL; NAFOXIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

BONE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE; HORMONE ACTION; HUMAN; HYPOPHYSIS; ICHTHYOSIS; ISCHEMIC HEART DISEASE; MOLECULAR MODEL; NONHUMAN; OSTEOPOROSIS; PHOTOPHOBIA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; UTERUS; UTERUS CANCER; VAGINA;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 0037501319     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet, 2: 104-107, 1896.
2. Boyd, S. On oophorectomy in cancer of the breast. BMJ, 2: 1161-1167, 1900.
3. Huggins, C., and Bergenstal, D. M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res., 12: 134-141, 1952.
4. Luft, R., and Olivecrona, H. Experiences with hypophysectomy in man. J. Neurosurg., 10: 301-316, 1953.
5. Haddow, A., Watkinson, J. M., and Paterson, E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ, 2: 393-398, 1944.
6. Lathrop, A. E., and Loeb, L. Further investigations on the origins of tumors in mice III on the part played by internal secretions in the spontaneous development of tumors. J. Cancer Res., 1: 1-19, 1916.
7. Allen, E., and Doisy, E. A. An ovarian hormone: preliminary report on its localization, extraction and partial purification and action in test animals. J. Am. Med. Assoc., 81: 819-821, 1923.
8. Lacassagne, A. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer, 27: 217-225, 1936.
9. Jensen, E. V., and Jacobson, H. I. Fate of steroidal estrogens in target tissues. In: G. Pincus and E. P. Vollmer (eds.), Biological Activities of Steroids in Relation to Cancer, pp. 161-174. New York: Academic Press, 1960.
10. Jensen, E. V., and Jacobson, H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res., 18: 318-414, 1962.
11. Toft, D., and Gorski, J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. USA, 55: 1574-1581, 1966.
12. Toft, D., Shyamala, G., and Gorski, J. A receptor molecule for estrogens: studies using a cell-free system. Proc. Natl. Acad. Sci. USA, 57: 1740-1743, 1967.
13. Jensen, E. V., Suzuki, T., Kawashima, T., Stumpf, W. E., Jungblut, P. W., and DeSombre, E. R. A two-step mechanism for the interaction of estradiol with rat uterus. Proc. Natl. Acad. Sci. USA, 59: 632-638, 1968.
14. Jensen, E. V., and DeSombre, E. R. Estrogenic hormone effect transformation of specific receptor proteins to a biochemically functional form. Science (Wash. DC), 182: 126-134, 1973.
15. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond.), 389: 753-758, 1997.
16. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95: 927-937, 1998.
17. Jensen, E. V., Block, G. E., Smith, S., Kyser, K., and DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. J. Natl. Cancer Inst. Monogr., 34: 55-70, 1971.
18. McGuire, W. L., Carbone, P. P., and Vollmer, E. P. Estrogen receptors in human breast cancer. New York: Raven Press, 1975.
19. Green, G. L., Closs, L. E., Fleming, H., De Sombre, E. R., and Jensen, E. V. Antibodies to estrogen receptor. Immunoclinical similarity of estrophilin from various mammalian species. Proc. Natl. Acad. Sci. USA, 74: 3681-3685, 1977.
20. Greene, G., Fitch, F. W., and Jensen, E. V. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc. Natl. Acad. Sci. USA, 77: 157-161, 1980.
21. Greene, G. L., Nolan, C., Engler, J. P., and Jensen, E. V. Monoclonal antibodies to human estrogen receptor. Proc. Natl. Acad. Sci. USA, 77: 5115-5119, 1980.
22. Jordan, V. C., Jacobson, H. I., and Keenan, E. J. Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. Cancer Res., 46: 4237s-4240s, 1986.
23. Greene, G. L., Sobel, N. B., King, W. J., and Jensen, E. V. Immunochemical studies of estrogen receptors. J. Steroid Biochem., 20: 51-56, 1984.
24. King, W. J., DeSombre, E. R., Jensen, E. V., and Green, G. L. Comparison of immunocytochemical and steroid binding assays for estrogen receptor in human breast tumors. Cancer Res., 45: 293-304, 1985.
25. Cole, M. P., Jones, C. T., and Todd, I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer, 25: 270-275, 1971.
26. Ward, H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J., 1: 13-14, 1973.
27. Jordan, V. C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat., 11: 197-209, 1988.
28. Emmens, C. W. Postcoital contraception. Br. Med. Bull., 26: 45-51. 1970.
29. The Wm. S. Merrell Company Clomiphene citrate (Clomid). Clin. Pharmacol. Therap., 8: 891-897, 1967.
30. Harper, M. J., and Walpole, A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature (Lond.), 212: 87, 1966.
31. Harper, M. J., and Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil., 13: 101-119, 1967.
32. Harper, M. J., and Walpole, A. L. Mode of action of ICI 46,474 in preventing implantation in rats. J. Endocrinol., 37: 83-92, 1967.
33. Bedford, G., and Richardson, D. N. Preparation and identification of cis and trans isomers of a substituted triphenylethylene. Nature (Lond.), 212: 733-734, 1966.
34. Klopper, A., and Hall, M. New synthetic agent for the induction of ovulation. Preliminary trial in women. Br. Med. J., 1: 152-154, 1971.
35. El-Sheikha, Z., Klopper, A., and Beck, J. S. Treatment of menometrorrhagia with antioestrogen. Clin. Endocrinol., 1: 275-282, 1972.
36. Williamson, J. G., and Ellis, J. D. The induction of ovulation by tamoxifen. J. Obstet. Gynaecol. Br. Commonw., 80: 844-847, 1973.
37. Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Bisel, H. F., Kvols, L. K., Nichols, W. C., Creagan, E. T., Hahn, R. G., Rubin, J., and Frytak, S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N. Engl. J. Med., 304: 16-21, 1981.
38. Huggins, C., Grand, L. C., and Brillantes, F. P. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and their suppression. Nature (Lond.), 189: 204, 1961.
39. Dao, T. L. The role of ovarian hormones in initiating the induction of mammary cancer in rats by polynuclear hydrocarbons. Cancer Res., 22: 973-978, 1962.
40. 3H]oestradiol by dimethylbenzanthracene-induced tumours. J. Endocrinol., 32: 83-88, 1965.
41. Mobbs, B. G. The uptake of triated oestradiol by dimethylbenzanthracene-induced mammary tumours of the rat. J. Endocrinol., 36: 409-414, 1966.
42. Skidmore, J. R., Walpole, A. L., and Woodburn, J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J. Endocrinol., 52: 289-298, 1972.
43. Jordan, V. C. Prolonged antioestrogenic activity of ICI 46,474 in the ovariectomized mouse. J. Reprod. Fertil., 42: 251-258, 1975.
44. Jordan, V. C., and Dowse, L. J. Tamoxifen as an antitumour agent: effect on oestrogen binding. J. Endocrinol., 68: 297-303, 1976.
45. Jordan, V. C., and Koerner, S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer, 11: 205-206, 1975.
46. Jordan, V. C., and Jaspan, T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J. Endocrinol., 68: 453-460, 1976.
47. Jordan, V. C., and Allen, K. E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer, 16: 239-251, 1980.
48. Jordan, V. C., Dix, C. J., and Allen, K. E. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adj. Ther. Cancer, 2: 19-26, 1979.
49. EBCTCG Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
50. Jordan, V. C. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J. Steroid Biochem., 5: 354, 1974.
51. Jordan, V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12: 419-424, 1976.
52. Powles, T. J., Hardy, J. R., Ashley, S. E., Farrington, G. M., Cosgrove, D., Davey, J. B., Dowsett, M., McKinna, J. A., Nash, A. G., and Sinnett, H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer, 60: 126-131, 1989.
53. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
54. Lerner, L. J., and Jordan, V. C. The development of antiestrogens for the treatment of breast cancer. Cancer Res., 50: 4177-4189, 1990.
55. Beall, P. T., Misra, K. L., Young, R. L., Spjut, H. J., Evan, H. J., and LeBlanc, A. Clomiphene protects against osteoporosis in the mature ovariectomized rat. Calcif. Tissue Int., 36: 123-125, 1985.
56. Schulz, K-D., Haselmayer, B., and Holzel, F. The influence of clomid and its isomers on dimethylbenzanthracene-induced rat mammary tumours. In: Basic Actions of Sex Steroids on Target Organs, pp. 274-279. Basel: Karger, 1971.
57. Jordan, V. C., Phelps, E., and Lindgren, J. U. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat., 10: 31-35, 1987.
58. Gottardis, M. M., and Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47: 4020-4024, 1987.
59. Turner, R. T., Wakley, G. K., Hannon, K. S., and Bell. N. H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology, 122: 1146-1150, 1988.
60. Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., Bensch, W. R., et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Investig., 93: 63-69, 1994.
61. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48: 812-815, 1988.
62. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Silfversward, C., Skoog, L., Somell, A., Theve, T., Wilking, N., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1: 117-120, 1989.
63. Black, L. J., Jones, C. D., and Falcone, J. F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci., 32: 1031-1036, 1983.
64. Buzdar, A. U., Marcus, C., Holmes, F., Hug, V., and Hortobagyi, G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology, 45: 344-345, 1988.
65. Turken, S., Siris, E., Seldin, D., Flaster, E., Hyman, G., and Lindsay, R. Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl. Cancer Inst. (Bethesda), 81: 1086-1088, 1989.
66. Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., and Demets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments]. N. Engl. J. Med., 326: 852-856, 1992.
67. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53: 3919-3924, 1993.
68. Phillips, D. H. Understanding the genotoxicity of tamoxifen? Carcinogenesis (Lond.), 22: 839-849, 2001.
69. Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., Christiansen, C., Delmas, P. D., Zanchetta, J. R., Stakkestad, J., Gluer, C. C., Krueger, K., Cohen, F. J., Eckert, S., Ensrud, K. E., Avioli, L. V., Lips, P., and Cummings, S. R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments]. J. Am. Med. Assoc., 282: 637-645, 1999.
70. Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., Lippman, M. E., Black, D., Glusman, J. E., Costa, A., and Jordan, V. C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc., 281: 2189-2197, 1999.
71. Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., Stephan, J. J., Powles, T. J., Morrow, M., Costa, A., Silfen, S. L., Walls, E. L., Schmitt, H., Muchmore, D. B., and Jordan, V. C. Continued breast cancer rusk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat., 65 (No. 2): 125-134, 2001.
72. Jordan, V. C., and Morrow, M. Raloxifene as a multifunctional medicine? BMJ, 319: 331-332, 1999.
73. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial. J. Am. Med. Assoc., 288: 321-333, 2002.
74. Baum, M., Brinkley, D. M., Dossett, J. A., McPherson, K., Patterson, J. S., Rubens, R. D., Smiddy, F. G., Stoll, B. A., Wilson, A., Lea, J. C., Richards, D., and Ellis, S. H. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer [letter]. Lancet, 2: 450, 1983.
75. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet., 2: 171-175, 1987.
76. Lieberman, M. E., Gorski, J., and Jordan, V. C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J. Biol. Chem., 258: 4741-4745, 1983.
77. Tate, A. C., Greene, G. L., DeSombre, E. R., Jensen, E. V., and Jordan, V. C. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res., 44: 1012-1018, 1984.
78. Lieberman, M. E., Jordan, V. C., Fritsch, M., Santos, M. A., and Gorski, J. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J. Biol. Chem., 258: 4734-4740, 1983.
79. Jordan, V. C. Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J. Lab. Clin. Med., 109: 267-277, 1987.
80. Walter, P., Green, S., Greene, G., Krust, A., Bornert, J. M., Jeltsch, J. M., Staub, A., Jensen, E., Scrace, G., Waterfield, M., et al. Cloning of the human estrogen receptor cDNA. Proc. Natl. Acad. Sci. USA, 82: 7889-7893, 1985.
81. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J. M., Argos, P., and Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (Lond.), 320: 134-139, 1986.
82. Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., and Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science (Wash. DC), 231: 1150-1154, 1986.
83. Wolf, D. M., and Jordan, V. C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat., 31: 129-138, 1994.
84. Catherino, W. H., Wolf, D. M., and Jordan, V. C. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol. Endocrinol., 9: 1053-1063, 1995.
85. Levenson, A. S., Catherino, W. H., and Jordan, V. C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol., 60: 261-268, 1997.
86. Levenson, A. S., and Jordan, V. C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res., 58: 1872-1875, 1998.
87. MacGregor-Shafer, J. I., Liu, H., Bentrem, D., Zapf, J., and Jordan, V. C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex by substituting glycine for aspartate at amino acid 351. Cancer Res., 60: 5097-5105, 2000.
88. Liu, H., Lee, E. S., De Los Reyes, A., Zapf, J. W., and Jordan, V. C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex. Cancer Res., 61: 3632-3639, 2001.
89. Bentrem, D., Dardes, R., Liu, H., MacGregor-Schafer, J., Zapf, J., and Jordan, V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology, 142: 838-846, 2001.
90. Liu, H., Park, W., Bentrem, D., McKian, K. P., De Los Reyes, A., MacGregor Schafer, J., Zapf, J., and Jordan, V. C. Structure-function relationships of the raloxifene-estrogen receptor α complex for regulating transforming growth factor alpha expression in breast cancer cells. J. Biol. Chem., 277: 9189-9198, 2002.
91. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines part I: receptor interactions. J. Med. Chem. 46: 883-908, 2003.
92. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines part II: clinical considerations and new agents. J. Med. Chem., 46: 1082-1111, 2003.
93. Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergot, I., Erikstein, B., Webster, A., and Morris, C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol., 20: 3396-3403, 2002.
94. Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R., and Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol., 20: 3386-3395, 2002.
95. The ATAC Trialist Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet, 359: 2131-2139, 2002.